Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones

被引:89
作者
Phillips, Oludotun A. [1 ]
Udo, Edet E. [2 ]
Abdel-Hamid, Mohammed E. [1 ]
Varghese, Reny [1 ]
机构
[1] Kuwait Univ, Dept Pharmaceut Chem, Fac Pharm, Safat 13110, Kuwait
[2] Kuwait Univ, Fac Med, Dept Microbiol, Safat 13110, Kuwait
关键词
Antibacterial; Linezolid; Monoamine oxidase; PH-027; 5-(4-Methyl-1,2,3-triazole)methyl oxazolidinone; Oxazolidinone; 5-TRIAZOLYLMETHYL OXAZOLIDINONES; NOSOCOMIAL INFECTIONS; AGENTS; 1,2,3-TRIAZOLES; IDENTIFICATION; AMINES;
D O I
10.1016/j.ejmech.2009.03.024
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 5-(4-methyl-1,2,3-triazole)methyl oxazolidinones were synthesized and tested for their antibacterial activity against a panel of Gram-positive and Gram-negative clinical isolates in comparison with linezolid and vancomycin. Most of the compounds demonstrated strong to moderate in vitro antibacterial activity against susceptible and resistant Gram-positive pathogenic bacteria. Antibacterial activity varied with substitutions at the phenyl C4 position with bulky alkylcarbonyl and alkoxycarbonyl substitutions on the piperazine N4 being detrimental to antibacterial activity. Whereas the presence of the 4-methyl-1,2,3-triazole moiety in the acyl-piperazine containing analogs resulted in increased protein binding, and decreased antibacterial activity particularly against Streptococcus pneumoniae strains. (C) 2009 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:3217 / 3227
页数:11
相关论文
共 24 条
[21]   Recent developments in the identification of novel oxazolidinone antibacterial agents [J].
Renslo, Adam R. ;
Luehr, Gary W. ;
Gordeev, Mikhail F. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (12) :4227-4240
[22]   REACTIONS OF ALPHA-POLYHALO KETONE TOSYLHYDRAZONES WITH SULFIDE ION AND PRIMARY AMINES - CYCLIZATION TO 1,2,3-THIADIAZOLES AND 1,2,3-TRIAZOLES [J].
SAKAI, K ;
HIDA, N ;
KONDO, K .
BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, 1986, 59 (01) :179-183
[23]  
Styers David, 2006, Ann Clin Microbiol Antimicrob, V5, P2
[24]  
Wiselka M, 2004, CLIN MED, V4, P494